Benitec Biopharma Ltd ADR (BNTC)

Nov 26, 2024, 7:00 AM EST - 7 weeks ago

Benitec Biopharma to Participate in Upcoming Investor Conferences in December

Nov 14, 2024, 4:30 PM EST - 2 months ago

Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update

Nov 4, 2024, 8:00 AM EST - 2 months ago

Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference

Oct 17, 2024, 3:35 PM EDT - 3 months ago

Benitec Biopharma: OPMD Program Continues To Advance With Catalysts

Oct 14, 2024, 6:00 AM EDT - 3 months ago

Benitec Biopharma Announces Updated Investor Webcast Information

Oct 12, 2024, 6:30 AM EDT - 3 months ago

Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society

Sep 26, 2024, 4:30 PM EDT - 4 months ago

Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update

Sep 18, 2024, 8:00 AM EDT - 4 months ago

Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society

Jul 15, 2024, 6:00 AM EDT - 6 months ago

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study

May 13, 2024, 8:15 AM EDT - 8 months ago

Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update

Apr 18, 2024, 7:30 AM EDT - 9 months ago

Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study

Apr 18, 2024, 7:00 AM EDT - 9 months ago

Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million

Feb 13, 2024, 8:00 AM EST - 1 year ago

Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update

Nov 30, 2023, 7:00 AM EST - 1 year ago

Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

Nov 17, 2023, 8:00 AM EST - 1 year ago

Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference

Nov 13, 2023, 8:00 AM EST - 1 year ago

Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update

Sep 21, 2023, 8:00 AM EDT - 1 year ago

Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update

Aug 11, 2023, 1:00 PM EDT - 1 year ago

Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering

Aug 8, 2023, 10:30 PM EDT - 1 year ago

Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering

Jul 25, 2023, 1:00 PM EDT - 1 year ago

Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023

Jun 26, 2023, 8:00 AM EDT - 1 year ago

Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

May 15, 2023, 8:00 AM EDT - 1 year ago

Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update

May 8, 2023, 8:05 AM EDT - 1 year ago

Benitec Biopharma to Present at the OPMD International Conference

Feb 13, 2023, 8:00 AM EST - 2 years ago

Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

Jan 23, 2023, 9:48 AM EST - 2 years ago

Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

Nov 10, 2022, 8:00 AM EST - 2 years ago

Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

Sep 16, 2022, 8:42 AM EDT - 2 years ago

Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

Sep 12, 2022, 10:06 PM EDT - 2 years ago

Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering

Sep 2, 2022, 8:00 AM EDT - 2 years ago

Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update

May 16, 2022, 8:15 AM EDT - 2 years ago

Benitec Biopharma Releases Q3 2022 Financial Results

Feb 14, 2022, 8:00 AM EST - 3 years ago

Benitec Biopharma Discloses Q2 2022 Financial Results

Nov 15, 2021, 8:00 AM EST - 3 years ago

Benitec Biopharma Discloses Q1 2022 Financial Results

Sep 20, 2021, 8:00 AM EDT - 3 years ago

Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results

Sep 13, 2021, 3:58 PM EDT - 3 years ago

Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference

Sep 8, 2021, 8:10 AM EDT - 3 years ago

Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022

Sep 8, 2021, 8:05 AM EDT - 3 years ago

Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals

Sep 8, 2021, 8:00 AM EDT - 3 years ago

Benitec Biopharma Provides Positive Regulatory Updates for the BB-301 Development Program; BB-301 Phase 1b/2a Clinical Trial to Begin in 2022

Apr 27, 2021, 9:55 PM EDT - 4 years ago

Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million

Apr 27, 2021, 4:44 PM EDT - 4 years ago

Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock

Mar 23, 2021, 5:03 PM EDT - 4 years ago

Benitec BioPharma Shares Rally: Technical Levels To Watch

Mar 23, 2021, 11:28 AM EDT - 4 years ago

Why DLPN Stock And BNTC Stock Are Popping Off Today

DLPN

Mar 23, 2021, 5:20 AM EDT - 4 years ago

Why Benitec Biopharma (BNTC) Stock Is Skyrocketing Today

Feb 24, 2021, 9:26 AM EST - 4 years ago

Benitec Biopharma's Gene Therapy For Rare Muscle Disorder Shows Encouraging Action In Animal Studies

Dec 7, 2020, 2:33 PM EST - 4 years ago

Benitec Biopharma Announces 2020 Annual Stockholder Meeting

Oct 6, 2020, 4:05 PM EDT - 4 years ago

Benitec Biopharma Announces Closing of $11.5 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares

Oct 2, 2020, 9:05 AM EDT - 4 years ago

Benitec Biopharma Announces Pricing of $10.0 Million Public Offering

Sep 23, 2020, 4:54 PM EDT - 4 years ago

Benitec Biopharma Provides Operational Update and Releases its 2020 Fiscal Year-End Financial Results

Sep 1, 2020, 8:15 AM EDT - 4 years ago

Benitec Biopharma to present at H.C. Wainwright's 22nd Annual Global Investment Conference

Jul 8, 2020, 8:00 AM EDT - 4 years ago

Benitec Biopharma Provides Update on BB-301 Tissue Transduction Study

Feb 28, 2020, 1:53 PM EST - 5 years ago

Penny Stocks to Buy Using Technical Analysis for March 2020

SUPV TRIB